v3.26.1
Segment and Geographic Information (Tables)
 12 Months Ended
Apr. 24, 2026
Segment Reporting [Abstract]  
Schedule of Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated
Segment Operating Profit
Fiscal Year 2026
(in millions)CardiovascularNeuroscienceMedical SurgicalTotal
Net sales$13,976 $10,287 $8,815 $33,079 
Reconciliation of revenues
Other operating segments net sales(1)
3,247 
Other adjustments(2)
39 
Total consolidated net sales$36,364 
Less:
Cost of products sold, excluding amortization of intangible assets4,695 3,151 3,476 11,323 
Research and development expense1,136 616 686 2,438 
Selling, general, and administrative expense4,519 3,421 2,511 10,451 
Other segment items(3)
(46)36 14 4 
Reportable segment operating profit$3,672 $3,062 $2,128 $8,862 
Reconciliation of segment profit / (loss)
Other operating segments profit(1)
106 
Currency and other(112)
Interest expense, net(715)
Other non-operating expense (income), net384 
Amortization of intangible assets(1,772)
Restructuring and associated costs(370)
Acquisition and divestiture-related items(173)
Certain litigation charges, net(113)
Other adjustments39 
Income before income taxes$6,136 
Fiscal Year 2025
(in millions)CardiovascularNeuroscienceMedical SurgicalTotal
Net sales$12,481 $9,846 $8,407 $30,734 
Reconciliation of revenues
Other operating segment net sales(1)
2,892 
Other adjustments(2)
(90)
Total consolidated net sales$33,537 
Less:
Cost of products sold, excluding amortization of intangible assets4,136 2,896 3,255 10,287 
Research and development expense1,020 612 665 2,298 
Selling, general, and administrative expense4,021 3,275 2,398 9,695 
Other segment items(3)
(41)31 18 8 
Reportable segment operating profit$3,344 $3,031 $2,071 $8,447 
Reconciliation of segment profit / (loss)
Other operating segments profit(1)
214 
Currency and other(14)
Interest expense, net(729)
Other non-operating expense (income), net402 
Amortization of intangible assets(1,807)
Restructuring and associated costs(303)
Acquisition and divestiture-related items(124)
Certain litigation charges, net(317)
Medical device regulations(52)
Other adjustments(2)
(90)
Income before income taxes$5,628 
 Fiscal Year 2024
(in millions)CardiovascularNeuroscienceMedical SurgicalTotal
Net sales$11,831 $9,406 $8,417 $29,654 
Reconciliation of revenues
Other operating segment net sales(1)
2,710 
Total consolidated net sales$32,364 
Less:
Cost of products sold, excluding amortization of intangible assets3,890 2,761 3,168 9,819 
Research and development expense991 624 646 2,261 
Selling, general, and administrative expense3,901 3,169 2,400 9,470 
Other segment items(3)
(28)30 9 11 
Reportable segment operating profit$3,078 $2,822 $2,193 $8,093 
Reconciliation of segment profit / (loss)
Other operating segments profit(1)
96 
Currency and other81 
Interest expense, net(719)
Other non-operating expense (income), net412 
Amortization of intangible assets(1,693)
Restructuring and associated costs(389)
Acquisition and divestiture-related items(777)
Certain litigation charges, net(149)
Medical device regulations(119)
Income before income taxes$4,837 
(1)Includes the operations and ongoing transition agreements from businesses the Company has exited, divested, or intends to separate, including the Diabetes Business.
(2)Includes adjustments to the Company's Italian payback accruals resulting from the two July 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government in June 2025 for certain prior years since 2015.
(3)Other segment items for each reportable segment primarily includes royalty expense. The Cardiovascular segment also includes income from funded research and development arrangements.
Schedule of Reconciliation of Assets and Depreciation Expense from Segments to Consolidated
Total Assets and Depreciation Expense
Total AssetsDepreciation Expense
(in millions)April 24, 2026April 25, 2025202620252024
Cardiovascular$17,553 $16,548 $253 $225 $199 
Neuroscience18,514 18,476 320 282 252 
Medical Surgical32,535 33,317 225 205 194 
Total reportable segments68,602 68,340 798 711 645 
Other operating segments (1)
4,827 4,433 127 113 94 
Corporate19,598 18,906 261 229 215 
Total$93,028 $91,680 $1,186 $1,054 $954 
(1)Includes the operations and ongoing transition agreements from businesses the Company has exited, divested, or intends to separate, including the Diabetes Business.
Schedule of Net Sales to External Customers and Property, Plant, and Equipment, Net, by Geographical Region
The following table presents net sales for fiscal years 2026, 2025, and 2024, and property, plant, and equipment, net at April 24, 2026 and April 25, 2025 for the Company's country of domicile, countries with significant concentrations, and all other countries:
Net salesProperty, plant, and equipment, net
(in millions)202620252024April 24, 2026April 25, 2025
Ireland$143 $116 $113 $338 $291 
United States18,103 17,171 16,562 5,455 5,133 
Rest of world18,118 16,250 15,689 1,623 1,414 
Total other countries, excluding Ireland36,221 33,421 32,251 7,078 6,547 
Total$36,364 $33,537 $32,364 $7,417 $6,837